Kevin M. Slawin, M.D., earned his medical degree at Columbia University before training in general and reconstructive surgery at Mount Sinai Hospital, New York. He returned to Columbia-Presbyterian Medical Center to complete his urological training under Carl Olsson, M.D., and subsequently was awarded a two-year AFUD fellowship with Peter Scardino, M.D., then chairman of the Scott Department of Urology, Baylor College of Medicine, to study the development and treatment of prostate cancer.
Dr. Slawin specializes in urologic oncology, diseases of the prostate, and reconstructive surgery. He has been a leader in the field of robotic surgery since its inception and is a founding editor of the Journal of Robotic Surgery. He was the first to perform robotic radical prostatectomy in the Texas Medical Center in 2001, and has since performed well over 700 robotic radical prostatectomies using a unique extra-peritoneal approach, recognized as technically more difficult to perform but yielding significant advantages to patient recovery.
His clinical research interests have focused more recently in improving cancer and quality of life outcomes after robotic and open prostate cancer surgery, and in developing new surgical techniques to treat more locally advanced, aggressive prostate cancers through a minimally invasive, robotic-assisted approach. In addition, he has a long history leading research studies investigating the molecular origins of benign prostatic hyperplasia (BPH) and ways of treating it with medical and minimally invasive therapy.
He is a co-discoverer of the novel molecular PSA form proPSA, which can be measured using a new, investigational blood test developed by Beckman Coulter, Inc. Dr. Slawin is leading Vanguard's participation in late-stage FDA pivotal trials of this blood test, in support of an application for FDA approval for use in men to improve the accuracy of prostate cancer screening. He has published extensively on other novel markers for the diagnosis, staging, and management of prostate and bladder cancer.
Recently, Dr. Slawin has been actively engaged in research and development of a new cancer vaccine that combines the most advanced biotechnologies, including cellular and gene therapy, to treat patients with a range of cancers, including prostate, breast, colon, and lung cancer. Clinical trials in patients with advanced, late-stage prostate cancer began in the fall of 2008 and are sponsored by Bellicum Pharmaceuticals, Inc. (www.bellicum.com) through the University of Texas Center for Clinical and Translational Science and the Memorial Hermann Center for Clinical Innovation and Research, which are associated with the Vanguard Urologic Institute.
Dr. Slawin has led the way in developing state-of-the-art treatment for prostate cancer, including cryotherapy and robotic prostatectomy, and improved surgical techniques that include the use of nerve grafts for preserving erectile function in men undergoing a retropubic prostatectomy and robotic laparoscopic radical prostatectomy using the da Vinci system. He recently received the F. Brantley Scott, M.D., Jr. Award for Innovation and Creativity in Urology.
Author of numerous papers on the subject of prostate cancer and BPH, Dr. Slawin is a section editor of Urology, a member of the Editorial Board of Reviews in Urology, a member of the Board of Consultants for the Journal of Urology, a consulting editor for the journal, Prostate Cancer and Prostatic Diseases, and serves as reviewer and consultant for several other scientific journals